Operating Income (Loss) in USD of Sigyn Therapeutics, Inc. from Q3 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Sigyn Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q3 2014 to Q3 2025.
  • Sigyn Therapeutics, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$387K, a 52.2% increase year-over-year.
  • Sigyn Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$1.88M, a 31.8% increase year-over-year.
  • Sigyn Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$2.52M, a 2.6% decline from 2023.
  • Sigyn Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$2.46M, a 14.3% decline from 2022.
  • Sigyn Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$2.15M, a 6.92% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Sigyn Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$1.88M -$387K +$422K +52.2% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$2.3M -$470K +$133K +22.1% 01 Apr 2025 30 Jun 2025 10-Q 05 Sep 2025
Q1 2025 -$2.44M -$546K +$83.9K +13.3% 01 Jan 2025 31 Mar 2025 10-Q 20 May 2025
Q4 2024 -$2.52M -$478K +$239K +33.4% 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2025
Q3 2024 -$2.76M -$808K -$166K -25.8% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$2.59M -$603K -$28.8K -5.02% 01 Apr 2024 30 Jun 2024 10-Q 05 Sep 2025
Q1 2024 -$2.56M -$630K -$109K -20.9% 01 Jan 2024 31 Mar 2024 10-Q 20 May 2025
Q4 2023 -$2.46M -$717K -$246K -52.1% 01 Oct 2023 31 Dec 2023 10-K 15 Apr 2025
Q3 2023 -$2.21M -$643K -$109K -20.5% 01 Jul 2023 30 Sep 2023 10-Q 19 Nov 2024
Q2 2023 -$2.1M -$574K -$41.2K -7.74% 01 Apr 2023 30 Jun 2023 10-Q 19 Aug 2024
Q1 2023 -$2.06M -$521K +$88K +14.4% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024
Q4 2022 -$2.15M -$472K +$119K +20.2% 01 Oct 2022 31 Dec 2022 10-K 20 Feb 2024
Q3 2022 -$2.27M -$534K +$39.7K +6.93% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$2.31M -$533K -$91K -20.6% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 -$2.22M -$609K -$207K -51.5% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 -$2.01M -$591K -$246K -71.5% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023
Q3 2021 -$1.76M -$573K -$370K -182% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$1.39M -$442K -$266K -151% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 -$1.13M -$402K -$209K -108% 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022
Q4 2020 -$916K -$345K -$343K -22130% 01 Oct 2020 31 Dec 2020 10-K 21 Mar 2022
Q3 2020 -$573K -$203K -$80.3K -65.4% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$493K -$176K -$74.6K -73.6% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021
Q1 2020 -$419K -$193K -$24.1K -14.3% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021
Q4 2019 -$394K -$1.55K +$241K +99.4% 29 Oct 2019 31 Dec 2019 10-K 06 Apr 2021
Q3 2019 -$635K -$123K +$119K +49.1% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020
Q2 2019 -$754K -$101K +$132K +56.5% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020
Q1 2019 -$885K -$169K +$119K +41.4% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020
Q4 2018 -$1M -$242K +$247K +50.5% 01 Oct 2018 31 Dec 2018 10-K 30 Mar 2020
Q3 2018 -$1.25M -$241K +$339K +58.4% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 -$1.59M -$233K +$382K +62.1% 01 Apr 2018 30 Jun 2018 10-Q 05 Aug 2019
Q1 2018 -$1.97M -$288K +$55.9K +16.3% 01 Jan 2018 31 Mar 2018 10-Q 19 Apr 2019
Q4 2017 -$2.03M -$489K 01 Oct 2017 31 Dec 2017 10-K 01 Apr 2019
Q3 2017 -$580K -$251K -76.1% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018
Q2 2017 -$615K -$88.4K -16.8% 01 Apr 2017 30 Jun 2017 10-Q 13 Aug 2018
Q1 2017 -$344K +$369K +51.7% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018
Q3 2016 -$2.37M -$329K +$487K +59.7% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2016
Q2 2016 -$2.86M -$527K -$43.6K -9.03% 01 Apr 2016 30 Jun 2016 10-Q 04 Aug 2016
Q1 2016 -$2.81M -$713K -$561K -369% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2016
Q4 2015 -$2.25M -$802K 01 Oct 2015 31 Dec 2015 10-K 30 Mar 2016
Q3 2015 -$817K -$738K -942% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016
Q2 2015 -$483K 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016
Q1 2015 -$152K 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016
Q3 2014 -$78.3K 01 Jul 2014 30 Sep 2014 10-Q 21 Dec 2015

Sigyn Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$2.52M -$63.9K -2.6% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025
2023 -$2.46M -$308K -14.3% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025
2022 -$2.15M -$139K -6.92% 01 Jan 2022 31 Dec 2022 10-K 20 Feb 2024
2021 -$2.01M -$1.09M -119% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023
2020 -$916K -$398K -76.9% 01 Jan 2020 31 Dec 2020 10-K 21 Mar 2022
2019 -$518K +$487K +48.4% 01 Jan 2019 31 Dec 2019 10-K 30 Mar 2020
2018 -$1M +$1.02M +50.5% 01 Jan 2018 31 Dec 2018 10-K 30 Mar 2020
2017 -$2.03M 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019
2015 -$2.25M -$1.87M -481% 01 Jan 2015 31 Dec 2015 10-K 30 Mar 2016
2014 -$388K 01 Jan 2014 31 Dec 2014 10-K 30 Mar 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.